What it's for (Indications)
- Citalopram (e.
- g.
- , Citalo) is primarily indicated for the treatment of Major Depressive Disorder (MDD) in adults.
- As a selective serotonin reuptake inhibitor (SSRI), it works by increasing serotonin levels in the brain, which is thought to help restore mental balance.
- The therapeutic effects typically manifest within several weeks of consistent use, with patients often experiencing improvements in mood, sleep, appetite, and energy levels, along with a reduction in feelings of anxiety or agitation associated with depression.
- It is essential that the diagnosis of MDD is established by a qualified healthcare professional before initiating citalopram therapy.
- While sometimes used off-label for other conditions like panic disorder or obsessive-compulsive disorder, its FDA-approved indication remains specific to MDD.
- Continued use under medical supervision is crucial to manage symptoms effectively and prevent relapse, often requiring long-term treatment depending on the individual's clinical presentation and response to therapy.
- Comprehensive psychiatric evaluation is recommended prior to treatment initiation.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of citalopram must be individualized and carefully titrated by a healthcare provider. For the treatment of Major Depressive Disorder in adults, the usual starting dose is 20 mg taken orally once daily, either in the morning or evening, with or without food. Based on clinical response and tolerability, the dose may be increased, typically in increments of 20 mg, after at least one week, up to a maximum recommended dose of 40 mg once daily. Doses above 40 mg/day are generally not recommended due to an increased risk of QTc prolongation, a potentially serious cardiac arrhythmia. For patients over 60 years of age, or those with hepatic impairment, the maximum recommended dose is 20 mg once daily, primarily due to reduced citalopram clearance and an elevated risk of QTc prolongation. It is critical to note that abrupt discontinuation of citalopram should be avoided to minimize the risk of withdrawal symptoms; doses should be gradually tapered under medical guidance when discontinuing treatment. Therapeutic benefits may take 2-4 weeks or longer to become fully apparent. |
Safety & Warnings
Common Side Effects
- Patients receiving citalopram may experience a range of side effects, some of which are generally mild and transient, while others can be more serious.
- Common adverse reactions, often dose-dependent, include nausea, dry mouth, somnolence, insomnia, increased sweating, tremor, diarrhea, and sexual dysfunction (e.
- g.
- , decreased libido, delayed ejaculation, anorgasmia).
- More serious, though less common, side effects necessitate immediate medical attention.
- These include Serotonin Syndrome, characterized by symptoms such as agitation, hallucinations, rapid heart rate, fever, muscle rigidity, and gastrointestinal disturbances, particularly when co-administered with other serotonergic agents.
- Citalopram can also cause QTc prolongation, potentially leading to Torsade de Pointes, a life-threatening cardiac arrhythmia; this risk is dose-dependent and heightened in individuals with pre-existing cardiac conditions or electrolyte imbalances.
- Other serious concerns include hyponatremia (low sodium levels), increased bleeding risk (especially with concomitant use of NSAIDs or anticoagulants), activation of mania/hypomania in patients with bipolar disorder, and seizures.
- Patients should be advised to report any concerning symptoms to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: Antidepressants, including citalopram, increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders compared to placebo. This risk must be balanced with the clinical need when considering use in these populations.
- Citalopram carries several important warnings, including a Black Box Warning concerning the increased risk of suicidal thoughts and behavior (suicidality) in children, adolescents, and young adults (up to 24 years of age) taking antidepressants for Major Depressive Disorder and other psychiatric disorders.
- Close monitoring for clinical worsening, suicidality, or unusual changes in behavior is paramount during initial treatment and dose adjustments in these populations.
- Another critical warning pertains to dose-dependent QTc prolongation, which can lead to ventricular arrhythmias, including Torsade de Pointes.
- Doses exceeding 40 mg/day are not recommended, and caution is advised for patients with congenital long QT syndrome, bradycardia, uncompensated heart failure, recent acute myocardial infarction, or electrolyte disturbances.
- Concomitant use with other QTc-prolonging drugs should be avoided.
- The risk of Serotonin Syndrome is elevated when citalopram is used with other serotonergic agents, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, and St.
- John's Wort.
- Patients should also be monitored for symptoms of hyponatremia, particularly the elderly or those on diuretics, and for increased bleeding risk, especially with concomitant use of antiplatelet agents or anticoagulants.
- Activation of mania or hypomania may occur in a small proportion of patients with mood disorders, necessitating careful screening for bipolar disorder prior to initiation.
- Abrupt discontinuation can lead to severe withdrawal symptoms, emphasizing the need for gradual dose tapering.
How it Works (Mechanism of Action)
Citalopram functions as a highly selective serotonin reuptake inhibitor (SSRI), primarily exerting its therapeutic effects by blocking the reuptake of serotonin (5-hydroxytryptamine or 5-HT) into the presynaptic neurons in the central nervous system. This inhibition of the serotonin transporter (SERT) leads to an increased concentration of serotonin in the synaptic cleft, thereby enhancing serotonergic neurotransmission. Unlike many older antidepressants, citalopram has minimal affinity for other neurotransmitter receptors, including muscarinic cholinergic, histaminic H1, alpha1-adrenergic, alpha2-adrenergic, or dopamine D1 and D2 receptors. This high selectivity for serotonin reuptake is believed to contribute to its relatively favorable side effect profile compared to tricyclic antidepressants. While the immediate pharmacological effect is the blockade of serotonin reuptake, the clinical antidepressant and anxiolytic effects are typically delayed by several weeks. This delay is attributed to complex adaptive changes in the postsynaptic serotonin receptors and neuronal circuits that occur in response to sustained increases in synaptic serotonin levels, ultimately restoring balance in mood-regulating pathways.